Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor

Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases plasma low-density lipoprotein cholesterol (LDL-C) by decreasing expression of the LDL receptor on hepatic cells. Evolocumab is a human monoclonal immunoglobulin G2 that binds specifically to human PCSK9 to reduce LDL-C. Evolocumab exhi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Pharmacokinet
Main Authors: Kasichayanula, Sreeneeranj, Grover, Anita, Emery, Maurice G., Gibbs, Megan A., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P.
Format: Artigo
Sprog:Inglês
Udgivet: Springer International Publishing 2018
Fag:
Review Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5999140/
https://ncbi.nlm.nih.gov/pubmed/29353350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-017-0620-7
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker